Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Philip Albaneze
Institution:
Roper St. Francis Healthcare
Observed institutions:
Fox Chase Cancer Center,
Roper St. Francis Healthcare
ORCID:
0009-0007-4100-1594
Observed ORCID:
0009-0007-4100-1594
OpenAlex ID:
A5074633972
Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening
2022
·
Rachel Hae-Soo Joung
, Timothy W. Mullett
, et al.
·
JAMA Network Open
·
31
PDF
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
2025
·
Adam M Brufsky
, Kent F Hoskins
, et al.
·
JNCI Cancer Spectrum
·
19
PDF
Does the false‐negative rate for 1 or 2 negative sentinel nodes after neo‐adjuvant chemotherapy translate into a high local recurrence rate?
2021
·
Nicole E. Sharp
, Darren B. Sachs
, et al.
·
The Breast Journal
·
5
Abstract P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
2025
·
Adam Brufsky
, Kent Hoskins
, et al.
·
Clinical Cancer Research
·
1
Show more works
View as search
Works count:
4
Citation count:
56
H-index:
3
I10-index:
2
Year
Topic
Type